

## **Intraprostatic Reflux of Urine Induces Inflammation in a Rat**

Yasuhito Funahashi <sup>1)</sup> \*, Tsuyoshi Majima <sup>1)</sup>, Yoshihisa Matsukawa <sup>1)</sup>, Tokunori Yamamoto <sup>1)</sup>, Masaki Yoshida <sup>2)</sup>, and Momokazu Gotoh <sup>1)</sup>

Department of Urology, <sup>1)</sup> Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan and <sup>2)</sup> National Center for Geriatrics and Gerontology, 35 Gengo, Morioka-cho, Ohbu 474-8511, Japan

Running head: Prostatitis by urine reflux

\*Corresponding author: Yasuhito Funahashi, MD., PhD. Mailing address: Department of Urology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan; Tel: +81-52-744-2985; Fax: +81-52-744-2319; E-mail address: yfunahashi@med.nagoya-u.ac.jp

Number of words in abstract: 251, Number of words in text: 2662, Number of figures and tables: 5 figures and 2 tables.

## **Abstract**

*Background:* We examined whether urine reflux into the prostate can induce prostatic inflammation in a rat and evaluated the effect of  $\alpha$ 1-adrenoreceptor antagonist.

*Methods:* Experiment 1: Male Sprague-Dawley rats were injected with 500  $\mu$ L of Evans Blue through the urethral orifice. Intravesical pressure was measured, and the prostate was excised to evaluate urine reflux. Experiment 2: Rats were injected with 500  $\mu$ L urine or saline (control) from the urethral orifice. Silodosin (200  $\mu$ g/kg/day) was administered to the silodosin group. We evaluated histopathology, the expression of proinflammatory cytokines and oxidative stress markers of the prostate on day 7, after assessing the prostatic microcirculation and cystometrogram.

*Results:* Experiment 1: The histopathology showed that Evans Blue instilled through the urethral orifice entered the prostatic ducts. Intravesical pressure during Evans Blue instillation was  $47.7 \pm 1.6$  cmH<sub>2</sub>O (mean  $\pm$  standard error). Experiment 2: On day 7 after urine instillation through the urethral orifice, histopathology showed infiltrated inflammatory cells in the peri-glandular stroma. Inflammation-associated proteins (IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, and TNF $\alpha$ ) were upregulated in the urine-instilled rats but not in the silodosin group. Erythrocyte speed on the prostatic surface, immunostaining for hypoxyprobe, and quantification of oxidative stress markers (MDA and HIF-1 $\alpha$ )

demonstrated prostatic hypoxia in the urine-instilled rats, which was ameliorated in the silodosin group. Cystometrogram revealed a shorter intercontraction interval in the urine-instilled rats, which was prolonged in the silodosin group.

*Conclusions:* Urine reflux into the prostatic duct induces abacterial prostatitis. Silodosin relieved prostatic inflammation and bladder overactivity by increasing microcirculation in the prostate.

Keywords: prostatitis, animal model, urine reflux, silodosin, microcirculation

### **Abbreviations**

IL; interleukin, TNF $\alpha$ ; Tumor necrosis factor  $\alpha$ , MDA; malondialdehyde, HIF-1  $\alpha$  ; hypoxia inducible factor-1  $\alpha$  , CP/CPPS; chronic prostatitis/chronic pelvic pain symptoms, PDE; phosphodiesterase, NSAIDs; nonsteroidal antiinflammatory drugs, PBS; phosphate buffered saline, ELISA; enzyme-linked immunosorbent assay, CCD; charge-coupled device, LUTS; lower urinary tract symptoms.

## **Introduction**

Prostatitis is categorized into four types based on the National Institutes of Health classification system; acute bacterial prostatitis, category I; chronic bacterial prostatitis, category II; chronic symptomatic abacterial prostatitis, category III; and chronic asymptomatic abacterial prostatitis, category IV.(1,2) Category III prostatitis is characterized by recurrent pelvic or perineal pain, dysuria, frequent urination, increased urgency, and unexplained fatigue. This type of prostatitis, which is a serious health concern that disturbs a patient's quality of life, is known as chronic prostatitis/chronic pelvic pain symptoms (CP/CPPS). The symptoms of category III prostatitis range from mild or negligible to severe; therefore, it is difficult to clearly distinguish category III from IV. Chronic abacterial prostatitis is the most common inflammatory prostatic disorder and exists widely among elderly men.(3) The Reduction by Dutasteride of Prostate Cancer Events trial suggested that chronic inflammation is found in >78% of men.(4) The Medical Therapy of Prostate Symptoms trial reported that about 40% of baseline biopsy specimens have chronic inflammatory infiltrates.(5)

Several mechanisms have been proposed to induce chronic inflammation in the prostate, including bacterial/viral infection,(6-10) changes in sex hormone secretion,(11) immunological reactions,(12) pelvic organ ischemia,(13) and urine reflux into the

prostatic ducts.(14) Reflux of urine into the prostatic ducts during micturition occurs in humans,(14) and can cause chemical irritation and inflammation. However, few studies have been conducted to examine the relationship between urine reflux and induction of inflammation.

Several types of drugs are used to treat CP/CPPS, including  $\alpha$ 1-adrenoreceptor antagonists, phosphodiesterase (PDE)-5 inhibitors, nonsteroidal antiinflammatory drugs (NSAIDs), and phytotherapeutic agents, but physicians occasionally encounter difficult-to-treat cases. A recent meta-analysis demonstrated that  $\alpha$ 1-adrenoreceptor antagonists is the most effective therapy among the above mentioned options,(15) however, the mechanism remains unknown. We hypothesized inflammation is diminished through the improvement of prostatic microcirculation.

In this study, we instilled urine into the prostatic duct and examined whether inflammation is induced. Also, we evaluated the effect of  $\alpha$ 1-adrenoreceptor antagonist on prostatic inflammation.

## **Materials and Methods**

All animal experiments were performed in accordance with institutional guidelines and

were approved by the Nagoya University Institutional Animal Care and Use Committee.

## Experiment 1

### *Intraprostatic reflux of transurethrally administered medium*

Twelve-week-old male Sprague-Dawley rats (n = 6) were anesthetized with isoflurane. The bladder was exposed with a lower midline abdominal incision, PE-50 tubing (Becton Dickinson, Parsippany, NJ, USA) was inserted into the bladder through the dome, and urine in the bladder was aspirated to empty the bladder. The intravesical catheter was connected to a pressure transducer, and intravesical pressure was measured using the Chart 7 software package (AD Instruments, Milford, MA, USA). The genital area was cleaned with 70% alcohol and the rats were subsequently catheterized with a PE-10 tubing into the urethra by 2 cm length. Then, 500  $\mu$ L of 2.5% Evans Blue in saline was infused in 5 sec using an insulin syringe. Ten min later, the prostate was dissected, rinsed with phosphate buffered saline (PBS), and frozen in compound. It was then cut into 8- $\mu$ m-thick sections, mounted on slides, and counterstained with eosin.

## Experiment 2

Twelve-week-old male SD rats were anesthetized with isoflurane in a supine position for

1 hour and the bladder was exposed through a lower abdominal incision. Next, 500  $\mu$ L of urine was removed using a 24 G needle stuck via the bladder dome. The genital area was cleaned with 70% alcohol and the rats were catheterized with a PE-10 tubing into the urethra by 2 cm length. Then, 500  $\mu$ L of urine or saline (control) was injected through the urethra in 5 sec using an insulin syringe, and the abdominal incision was closed. Osmotic pumps (Alzet; Durect Inc., Cupertino, CA, USA) containing silodosin (Kissei Pharmaceutical Co. Ltd, Matsumoto, Japan) (200  $\mu$ g/kg/day when released at a rate of 1.0  $\mu$ L/h for 7 days) were implanted subcutaneously in the back in the silodosin group.

#### *Histological analyses*

The excised prostate and bladder were frozen immediately in compound, cut into 8- $\mu$ m-thick sections, and mounted on slides. The tissue sections were fixed in 4% paraformaldehyde and stained with hematoxylin and eosin. Histological changes in the prostate were graded according to the following scale: 0, no evidence of inflammatory infiltration or stromal edema; 1, mild (few inflammatory cells and little or no stromal edema); 2, moderate (infiltration of a moderate number of inflammatory cells and moderate stromal edema); and 3, severe (diffuse presence of many infiltrating

inflammatory cells and severe stromal edema). A single blinded observer graded the prostatic histological scores.

#### *Hypoxyprobe-immunostaining*

The rats were injected intraperitoneally with pimonidazole hydrochloride (Hypoxyprobe<sup>TM</sup>-1, 60 mg/kg; Hypoxyprobe Inc., Burlington, MA, USA) 1 h before sacrifice. The excised prostate was frozen immediately in compound, cut into 10- $\mu$ m-thick sections, and mounted on slides. The tissues were fixed with 4% paraformaldehyde for 10 min, rinsed with PBS, transferred to 3% hydrogen peroxide for 10 min to block peroxidase activity, and rinsed with distilled water and PBS. Next, the sections were blocked with 5% normal goat serum (Vector, Burlingame, CA, USA) for 1 h. Without rinsing, the tissues were reacted with anti-pimonidazole mouse IgG<sub>1</sub> monoclonal antibody for 40 min at room temperature and washed with PBS. The tissues were incubated for 10 min with biotinylated anti-mouse antibody (Dako, Carpinteria, CA, USA) at room temperature and rinsed with PBS. The tissues were stained with streptavidin-horseradish peroxidase (Dako) for 10 min followed by diaminobenzidine and nickel–ammonium sulfate with hydrogen peroxide (Vector). The tissues were counterstained in hematoxylin.



*Measurement of inflammatory markers and oxidative stress markers*

Prostate tissues (n = 6 per groups) were homogenized in RIPA lysis buffer. The homogenate was centrifuged at 10,000 rpm for 10 min and the supernatants were stored at  $-80^{\circ}\text{C}$  until assayed. Interleukin (IL)-1 $\alpha$ , IL-1 $\beta$ , IL-6, and tumor necrosis factor (TNF)- $\alpha$  levels were determined on the MAGPIX (Millipore, Billerica, MA, USA) using the MILLIPLEX MAP Rat Cytokine/Chemokine Panel (Millipore). Malondialdehyde (MDA) and hypoxia inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) expression levels were measured using specific enzyme-linked immunosorbent assay (ELISA) kits (Nikken, Shizuoka, Japan and Cell Biolabs, Tokyo, Japan, respectively). Protein concentration was determined using a Bio-Rad kit (Hercules, CA, USA) with bovine serum albumin as the standard. The concentrations of the target proteins were standardized to tissue protein levels and expressed as pg/mg total protein for IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, TNF- $\alpha$ , and HIF-1 $\alpha$  and as n mol/mg total protein for MDA.

*Measurement of erythrocyte speed on the prostate surface*

The rats (n = 6 per groups) were anesthetized with isoflurane on day 7. The ventral lobes of the prostate was exposed with a lower midline abdominal incision, and the erythrocyte

speed on the prostate surface was measured using the pencil lens charge-coupled device (CCD) microscopy system; a video recorder (DV-CAM, Sony Co., Tokyo, Japan) and monitor, lighting apparatus, controller, camera, lighting guide, and pencil lens with a spatial resolution of 0.86  $\mu\text{m}$  and time resolution of 33 ms. Using an adjustable micromanipulator with a precision of a few tens of microns in the X, Y, and Z axes, the tip of the conical lens was secured in a position 30–50  $\mu\text{m}$  from the prostate surface, allowing blood flow in the prostatic surface capillaries to be observed in real time. The reflected image was captured and passed through a green filter and converted to electrical signals in a CCD camera. The velocity at which red blood cells travelled through single capillaries of the prostate was measured from sequences of pictures.(16)

#### *Conscious cystometry*

The rats (n = 6 per groups) were anesthetized with isoflurane on day 7. The bladder was exposed with a lower midline abdominal incision, and PE-50 tubing was inserted into the bladder through the dome. The anesthesia was turned off and conscious rats were placed in a recording cage (Natsume Seisakusho Co., Tokyo, Japan). Saline was infused transvesically at 0.04 mL/min after 2 h of accumulation, and the rats voided spontaneously through the urethra. At least four reproducible micturition cycles were

recorded after an initial stabilization period (60 min). Baseline pressure, voiding pressure threshold, peak voiding pressure, and intercontraction interval were evaluated.(17,18)

### *Statistics*

All data are expressed as means  $\pm$  standard errors. The nonparametric Mann–Whitney U-test was used to assess differences between groups. All tests were two-sided, and p-values  $< 0.05$  were considered statistically significant. All statistical analyses were performed using the SPSS software package (SPSS Inc., Chicago, IL, USA).

## **Results**

### Experiment 1

#### *Reflux of trans-urethrally instilled fluid into the prostatic ducts*

First, we instilled 500  $\mu\text{L}$  of 2.5% Evans Blue through the urethral orifice in 5 s. The maximum intravesical pressure during instillation was  $47.7 \pm 1.6$  cm  $\text{H}_2\text{O}$ . Histology of the excised prostate showed that the Evans Blue occupied the prostatic ducts and was exuded into some parts of the stromal area (Fig. 1). This result showed that 500  $\mu\text{L}$  of trans-urethrally instilled fluid inflow into the prostatic ducts.

## Experiment 2

### *Histological examination*

Next, we instilled 500  $\mu$ L of urine or saline through the urethral orifice. On day 7, the stromal area expanded apparently in the urine-instilled rats with polymorphological cells diffusely throughout the prostate. There were no inflammatory cells in the acini in contrast to the bacterial prostatitis model. No histological changes were observed in the bladder. In the silodosin group, stromal inflammation was observed, but at the lesser extent (Fig. 2).

### *Inflammation- and hypoxia-associated protein expression levels*

ELISA showed that tissue levels of the proinflammatory cytokines IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, and TNF- $\alpha$  were upregulated in the prostates of the urine-instilled rats, but tended to be decreased in the silodosin-treated rats. We observed similar changes in the expression of the hypoxia-associated proteins, MDA and HIF-1 $\alpha$  (Table 1). No group differences in the levels of these proteins in the bladder were observed.

### *Quantification of prostate microcirculation*

The diameter of microvessels on the prostatic surface was smaller in the urine-instillation group and was normalized in the silodosin group (Fig. 3). Erythrocyte speed on the prostatic surface was  $166.9 \pm 6.2 \mu\text{m/s}$  in the control group; the speed was significantly slower in the urine instillation group ( $142.9 \pm 3.0 \mu\text{m/s}$ ,  $p = 0.034$  compared to controls) but did not differ from that of the silodosin group ( $150.9 \pm 4.0 \mu\text{m/s}$ ,  $p = 0.192$  compared to controls).

#### *Hypoxyprobe staining*

Hypoxyprobe immunostaining demonstrated weak positivity, mainly in the epithelium of the control rats. Much stronger positive staining was seen in the urine-instilled rats, which was normalized in the silodosin-treated rats (Fig. 4).

#### *Cystometric analysis of bladder function*

The intercontraction interval in control rats was  $1818 \pm 126$  sec. The urine-instilled rats exhibited bladder overactivity, as evidenced by frequent micturition ( $993 \pm 58$  sec, respectively,  $p < 0.001$  compared to controls). The intercontraction intervals were prolonged in the silodosin group ( $1607 \pm 150$  sec,  $p < 0.001$  compared to controls; Fig. 5 and Table 2).

## **Discussion**

This study revealed five major findings. First, when rats were instilled with 500  $\mu$ L of medium from the urethral orifice, some of the medium flew into the prostatic duct. Intravesical pressure during instillation was not as high as it injured the bladder. Second, abacterial prostatitis was induced by inflow of urine into the prostatic ducts, which was characterized by inflammatory cell infiltration in the expanded stroma. Third, microcirculation was disturbed on the surface of the inflamed prostate. Fourth, urine-instilled rats showed bladder overactivity, as evidenced by frequent micturition. Finally, silodosin suppressed prostatic oxidative stress and relieved the bladder overactivity.

There is some evidence that urine reflux occurs during normal voiding in humans.(14) Kirby et al. instilled a carbon particle suspension in the bladders of male human cadavers and found that carbon flew into the prostatic duct in all cases after 20 min of maintaining intravesical pressure of 50 cmH<sub>2</sub>O. They also instilled 400 mL of the carbon particle suspension into the bladders of patients with benign prostatic hyperplasia prior to transurethral resection of the prostate. They asked the patients to void and found

intraductal carbon present in 70% of cases. They also showed that prostatic calculi are composed partly of urine ingredients. The constituents of refluxing urine may contribute to the formation of prostatic stones by precipitation of minerals upon existing corpora amylacea.(19) The association between high urate concentration in an expressed prostatic secretion and the symptoms of patients with nonbacterial prostatitis is also evidence of urine reflux into the prostatic ducts.(20)

Several prostatitis models have been reported, including spontaneous, bacteria, auto-immune, thymectomy, hormone, stress, chemical, and diet-induced models.(21) Some of these models are based on the concept of transurethraly instilled medium upflow into the prostate. *E. coli* administered through the urethra causes bacterial prostatitis.(22) Transurethral ethanol/dinitrobenzenesulfonic acid-mediated mucosal injury results in acute prostatitis that peaks at 24–48 h.(23) These models irritate both prostate and bladder; therefore, they are not appropriate to evaluate the effect of prostatic inflammation on bladder function. We instilled rat urine and no injuries were observed in the bladders, therefore, we can conclude that prostatic inflammation causes bladder overactivity.

Some other studies reported prostatitis rat models of intraprostatic urinary inflow secondary to partial urethral obstruction. Takechi et al. ligated the proximal

urethra and reported that low molecular weight substances in the urine penetrated prostatic stromal tissue, which resulted in prostatic lymphocytic infiltration and interstitial edema that was most prominent on day 3.(24) After releasing the nylon ligature from the urethra, the prostatic inflammatory changes disappeared gradually. Melman et al. compared two partial urethral obstruction techniques, namely bulbous urethral obstruction through a perineal incision and midprostatic obstruction using a retropubic approach.(25) They reported that a midprostatic urethral obstruction caused bacterial prostatitis and a bulbous urethral obstruction induced a few areas of mild inflammation in the acini and adjacent interstitium with most of the normal prostatic tissue.

Some authors have reported decreased prostatic blood flow in disease conditions in both humans and animals. Berger et al. found significantly reduced prostatic perfusion in men at high risk for lower urinary tract symptoms (LUTS) using contrast-enhanced color Doppler ultrasonography.(13) Zarifpour et al. demonstrated that chronic prostatic ischemia significantly increases the contractile response of isolated prostatic tissue to electrical and pharmacological stimulation, as well as smooth muscle  $\alpha$ -actin and collagen deposition.(26) Thurmond et al. found that oxidative modifications of cellular and subcellular elements increase contractions of prostate tissue under ischemic



conditions. They found that cultured human prostate smooth muscle cells, epithelial cells, and stromal cells were highly sensitive to hypoxic and oxidative stress conditions.(27) Our data also showed that the prostate microcirculation was disturbed in the abacterial prostatitis model, probably due to compression of the microvessels by edematous stroma.

Several drugs are used to treat chronic prostatitis, including  $\alpha$ 1-adrenoreceptor antagonists, PDE-5 inhibitors, NSAIDs, and phytotherapeutic agents.(15) A meta-analysis demonstrated that  $\alpha$ 1-adrenoreceptor antagonists are more effective than NSAIDs or phytotherapy(15) and a recent guideline recommended  $\alpha$ 1-adrenoreceptor antagonists as the initial treatment option.(28) Shimizu et al. showed that silodosin increased prostatic blood flow and suppressed oxidative stress, inflammatory cytokines, growth factors and morphological abnormalities in the ventral prostate of spontaneously hypertensive rats.(29) Although the mechanisms by which  $\alpha$ 1-adrenoreceptor antagonists relieve prostatitis symptoms have not been fully elucidated, this study demonstrated the possibility that the improvement in prostate blood flow that results from blocking the  $\alpha$ 1A subtype in vascular smooth muscle might be one mechanism.

This study has several limitations. We evaluated histological and hemodynamic changes only in the ventral lobe of the prostate. We did not examine the dose-response relation or time-course change of silodosin. Instilled urine may not be homogenous in

gradients among rats and the urine ingredient that was acting as an irritant was not unknown. Uric acid crystals result in the development of chronic prostatic inflammation by activating the NALP3 inflammasome;(30) normalization of uric acid levels is effective for improving prostatitis symptoms.(31) Proton ions, potassium ions, and ammonium in urine are also possible candidates. Further studies to identify the irritant or to use standardized urine sample are required in the future.

## **Conclusions**

We evaluated the influence of urine reflux into the prostatic duct on the prostatic inflammatory reaction and voiding function. Urine reflux into the prostatic duct induced abacterial prostatitis and frequent micturition. Silodosin improved prostatic hypoxia by increasing blood flow, which suppressed prostatic inflammation and bladder overactivity.

## **Conflicts of interest**

This study was supported by Dai-ichi Sankyo Pharmaceutical.

## **Figure Legends**

### **Figure 1. Evans-Blue reflux into the prostate**

The prostate was evaluated histologically after instillation of 500  $\mu\text{L}$  of Evans Blue through the urethra. Evans Blue was observed in the prostatic duct (white arrowhead in A) and spilled out in some parts (black arrow head in B). Scale bar: 100  $\mu\text{m}$ .

### **Figure 2. Hematoxylin and eosin staining of the prostate and bladder**

Compared with control prostate (A), increased submucosal edema and inflammatory cell infiltrates were observed in the urine-instilled rats (B). Diffuse inflammation was observed in the silodosin group also (C). No inflammation was observed in the bladder of any of the groups (D; control, E; urine-instilled group, and F; silodosin group). Scale bar indicates 100  $\mu\text{m}$  (A to C) and 200  $\mu\text{m}$  (D to F).

### **Figure 3. Microvessels on the prostate surface**

Pencil lens CCD microscopy directly visualized the movement of each erythrocyte. Compared to the control (A), the microvessels had smaller diameters in the urine-instillation group (B), which was larger in the silodosin group (C). Scale bar: 50  $\mu\text{m}$ .

**Figure 4. Immunohistochemistry for hypoxyprobe**

Hypoxyprobe staining was stronger mainly in the epithelium of the urine-instilled rats, which was normalized in the silodosin-treated rats. Scale bar: 100  $\mu$ m.

**Figure 5. Cystomegrogram**

Representative intravesical pressure was demonstrated. Compared to the control (A), the intercontraction interval was shorter in the urine-instilled group (B) and was prolonged in the silodosin-treated group (C). Scale bar: 10 min.

## References

1. National Institutes of Health Summary Statement. National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases workshop on chronic prostatitis. Executive Summary. Bethesda, Maryland December 1995.
2. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. *Urology* 1999;54(2):229-233.
3. Zhang R, Sutcliffe S, Giovannucci E, Willett WC, Platz EA, Rosner BA, Dimitrakoff JD, Wu K. Lifestyle and risk of chronic prostatitis/chronic pelvic pain syndrome in a cohort of US male health professionals. *The Journal of urology* 2015;in press.
4. Nickel JC, Roehrborn CG, O'Leary M P, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. *The Journal of urology* 2007;178(3 Pt 1):896-900; discussion 900-891.
5. Roehrborn CG. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. *The Journal of urology* 2005;173(4):346.
6. Montagnini Spaine D, Mamizuka EM, Pereira Cedenho A, Srougi M. Microbiologic aerobic studies on normal male urethra. *Urology* 2000;56(2):207-210.
7. Willen M, Holst E, Myhre EB, Olsson AM. The bacterial flora of the

- genitourinary tract in healthy fertile men. *Scandinavian journal of urology and nephrology* 1996;30(5):387-393.
8. Mak TN, Yu SH, De Marzo AM, Bruggemann H, Sfanos KS. Multilocus sequence typing (MLST) analysis of *Propionibacterium acnes* isolates from radical prostatectomy specimens. *The Prostate* 2013;73(7):770-777.
  9. Krieger JN, Riley DE. Chronic prostatitis: Charlottesville to Seattle. *The Journal of urology* 2004;172(6 Pt 2):2557-2560.
  10. Xiao J, Ren L, Lv H, Ding Q, Lou S, Zhang W, Dong Z. Atypical microorganisms in expressed prostatic secretion from patients with chronic prostatitis/chronic pelvic pain syndrome: microbiological results from a case-control study. *Urologia internationalis* 2013;91(4):410-416.
  11. Straub RH. The complex role of estrogens in inflammation. *Endocrine reviews* 2007;28(5):521-574.
  12. Kouivaskaia DV, Southwood S, Berard CA, Klyushnenkova EN, Alexander RB. T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome. *The Journal of urology* 2009;182(5):2483-2489.
  13. Berger AP, Horninger W, Bektic J, Pelzer A, Spranger R, Bartsch G, Frauscher F. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? *BJU international* 2006;98(3):587-590.
  14. Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. *British journal of urology* 1982;54(6):729-731.
  15. Thakkestian A, Attia J, Anothaisintawee T, Nickel JC. alpha-blockers, antibiotics

- and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome. *BJU international* 2012;110(7):1014-1022.
16. Mizuno H, Yamamoto T, Okutsu H, Ohtake A, Sasamata M, Matsukawa Y, Funahashi Y, Kato M, Hattori R, Gotoh M. Effect of tamsulosin on bladder microcirculation in a rat ischemia-reperfusion model, evaluated by pencil lens charge-coupled device microscopy system. *Urology* 2010;76(5):1266.e1261-1265.
  17. Funahashi Y, Yoshida M, Yamamoto T, Majima T, Takai S, Gotoh M. Intravesical application of rebamipide promotes urothelial healing in a rat cystitis model. *The Journal of urology* 2014;192(6):1864-1870.
  18. Funahashi Y, Yoshida M, Yamamoto T, Majima T, Takai S, Gotoh M. Intravesical application of rebamipide suppresses bladder inflammation in a rat cystitis model. *The Journal of urology* 2014;191(4):1147-1152.
  19. Sutor DJ, Wooley SE. The crystalline composition of prostatic calculi. *British journal of urology* 1974;46(5):533-535.
  20. Persson BE, Ronquist G. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. *The Journal of urology* 1996;155(3):958-960.
  21. Vykhovanets EV, Resnick MI, MacLennan GT, Gupta S. Experimental rodent models of prostatitis: limitations and potential. *Prostate cancer and prostatic diseases* 2007;10(1):15-29.
  22. Funahashi Y, Wang Z, O'Malley KJ, Tyagi P, DeFranco DB, Gingrich JR, Takahashi R, Majima T, Gotoh M, Yoshimura N. Influence of E. coli-induced

- prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. *The Prostate* 2015;75(4):381-389.
23. Lang MD, Nickel JC, Olson ME, Howard SR, Ceri H. Rat model of experimentally induced abacterial prostatitis. *The Prostate* 2000;45(3):201-206.
  24. Takechi S, Yokoyama M, Tanji N, Nishio S, Araki N. Nonbacterial prostatitis caused by partial urethral obstruction in the rat. *Urological research* 1999;27(5):346-350.
  25. Melman A, Tar M, Boczko J, Christ G, Leung AC, Zhao W, Russell RG. Evaluation of two techniques of partial urethral obstruction in the male rat model of bladder outlet obstruction. *Urology* 2005;66(5):1127-1133.
  26. Zarifpour M, Nomiya M, Sawada N, Andersson KE. Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. *The Prostate* 2015;75(3):233-241.
  27. Thurmond P, Yang JH, Li Y, Lerner LB, Azadzo KM. Structural modifications of the prostate in hypoxia, oxidative stress, and chronic ischemia. *Korean journal of urology* 2015;56(3):187-196.
  28. Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. *BJU Int* 2015;116(4):509-525.
  29. Shimizu S, Shimizu T, Tsounapi P, Higashi Y, Martin DT, Nakamura K, Honda M, Inoue K, Saito M. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. *PLoS One* 2015;10(8):e0133798.



30. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* 2006;440(7081):237-241.
31. Motrich RD, Olmedo JJ, Molina R, Tissera A, Minuzzi G, Rivero VE. Uric acid crystals in the semen of a patient with symptoms of chronic prostatitis. *Fertility and sterility* 2006;85(3):751.e751-751.e754.